Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Crupi

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Frontiers in Immunology|January 30, 2023
CRISPR-mediated rapid arming of poxvirus vectors enables facile generation of the novel immunotherapeutic STINGPOXJack T Whelan, Ragunath Singaravelu, Fuan Wang, et al.
Frontiers in Immunology|November 21, 2022
Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancerMathieu J F Crupi, Zaid Taha, Thijs J A Janssen, et al.
Frontiers in Immunology|March 27, 2023
Fatty acid transport protein inhibition sensitizes breast and ovarian cancers to oncolytic virus therapy <i>via</i> lipid modulation of the tumor microenvironmentAbera Surendran, Monire Jamalkhah, Joanna Poutou, et al.
The Journal of Experimental Medicine|June 13, 2024
PD-L1 promotes oncolytic virus infection via a metabolic shift that inhibits the type I IFN pathwayJonathan J Hodgins, John Abou-Hamad, Colin Edward O'Dwyer, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 8, 2022
Identification of FDA-approved bifonazole as a SARS-CoV-2 blocking agent following a bioreporter drug screenZaid Taha, Rozanne Arulanandam, Glib Maznyi, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 23, 2021
Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infectionStephen Boulton, Joanna Poutou, Nikolas T Martin, et al.
Nature Communications|April 8, 2022
Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapyMarie-Eve Wedge, Victoria A Jennings, Mathieu J F Crupi, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Frontiers in Immunology|January 30, 2023
CRISPR-mediated rapid arming of poxvirus vectors enables facile generation of the novel immunotherapeutic STINGPOXJack T Whelan, Ragunath Singaravelu, Fuan Wang, et al.
Frontiers in Immunology|November 21, 2022
Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancerMathieu J F Crupi, Zaid Taha, Thijs J A Janssen, et al.
Frontiers in Immunology|March 27, 2023
Fatty acid transport protein inhibition sensitizes breast and ovarian cancers to oncolytic virus therapy <i>via</i> lipid modulation of the tumor microenvironmentAbera Surendran, Monire Jamalkhah, Joanna Poutou, et al.
The Journal of Experimental Medicine|June 13, 2024
PD-L1 promotes oncolytic virus infection via a metabolic shift that inhibits the type I IFN pathwayJonathan J Hodgins, John Abou-Hamad, Colin Edward O'Dwyer, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 8, 2022
Identification of FDA-approved bifonazole as a SARS-CoV-2 blocking agent following a bioreporter drug screenZaid Taha, Rozanne Arulanandam, Glib Maznyi, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 23, 2021
Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infectionStephen Boulton, Joanna Poutou, Nikolas T Martin, et al.
Nature Communications|April 8, 2022
Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapyMarie-Eve Wedge, Victoria A Jennings, Mathieu J F Crupi, et al.
Pageof 4